← FDA DRUG APPROVALS

FDA NDA · NDA018144

CENTRAX

Sponsor: PARKE DAVIS

APPLICATION
NDA018144
TYPE
NDA
ORIGINAL APPROVAL
1979-11-30
LATEST ACTION
1996-04-26
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

CENTRAXDiscontinued
PRAZEPAM 10MG · CAPSULE · ORAL
CENTRAXDiscontinued
PRAZEPAM 20MG · CAPSULE · ORAL
CENTRAXDiscontinued
PRAZEPAM 5MG · CAPSULE · ORAL

Approval history

1996-04-26Labeling · Supplement 16 · standardAP
1996-04-26Labeling · Supplement 9AP
1996-04-26Labeling · Supplement 15 · standardAP
1996-04-26Labeling · Supplement 13AP
1996-04-26Labeling · Supplement 11AP
1984-05-01Labeling · Supplement 8AP
1980-05-27Labeling · Supplement 1AP
1979-11-30Type 3 - New Dosage Form · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →